Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | L'Oréal SA | 294 |
| 2 | Cyclerion Therapeutics Inc | 65 |
| 3 | Nissan Chemical Corp | 57 |
| 4 | Bayer AG | 54 |
| 5 | Ironwood Pharmaceuticals Inc | 53 |
| 6 | Nicox SA | 52 |
| 7 | Chugai Pharmaceutical Co Ltd | 51 |
| 8 | Redx Pharma Ltd | 43 |
| 9 | Bristol Myers Squibb Co | 36 |
| 10 | BASF SE | 32 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 1,684 |
| 2 | A61P | Therapeutic activity (drug indications) | 1,577 |
| 3 | C07D | Heterocyclic compounds | 1,230 |
| 4 | A61Q | Cosmetics, personal care | 573 |
| 5 | C07C | Acyclic and carbocyclic compounds | 354 |
| 6 | Y02A | Climate change adaptation | 238 |
| 7 | C07K | Peptides | 168 |
| 8 | C07F | Organometallic compounds | 145 |
| 9 | A45D | 106 | |
| 10 | A01N | Preservation of bodies; biocides; pest repellents | 102 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Treatment of sexual dysfunction with N-hydroxyguanidine compounds | 2001 | NITROMED, INC. | 48 |
| Substd hydroxyguanidines prepn | 1972 | FAHLBERG LIST VEB | 26 |
| Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | 2009 | Heidelberg Pharma AG | 23 |
| N-HYDROXYGUANIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | 2007 | Incyte Corp | 23 |
| Use of hydroxyguanidines | 2003 | WAPHARM AB | 11 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Amino Acid Enzymes and Metabolism | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Daniel Mansuy | Université Paris Cité | 13 |
| 2 | Jean‐Luc Boucher | Université Paris Cité | 12 |
| 3 | Bernd Clement | Christian-Albrechts-Universität zu Kiel | 6 |
| 4 | Dennis J. Stuehr | Université Paris Cité | 5 |
| 5 | David Lefèvre‐Groboillot | Université Paris Cité | 4 |
| 6 | Jarl E. S. Wikberg | Uppsala University | 4 |
| 7 | Jon M. Fukuto | Oklahoma State University Center for Health Sciences | 4 |
| 8 | Maija Dambrova | Uppsala University | 4 |
| 9 | Bernard Müller | Centre National de la Recherche Scientifique | 3 |
| 10 | Dennis Schade | Christian-Albrechts-Universität zu Kiel | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Arginase: Structure, Mechanism, and Physiological Role in Male and Female Sexual Arousal | 2005 | 163 | Sexual function and dysfunction studies |
| The Novel Binding Mode of <i>N</i>-Alkyl-<i>N</i>‘-hydroxyguanidine to Neuronal Nitric Oxide Synthase Provides Mechanistic Insights into NO Biosynthesis | 2002 | 116 | Nitric Oxide and Endothelin Effects |
| Chemical oxidation of N-hydroxyguanidine compounds | 1992 | 114 | Nitric Oxide and Endothelin Effects |
| Structure and dynamics of cationic membrane peptides and proteins: Insights from solid‐state NMR | 2011 | 96 | Lipid Membrane Structure and Behavior |
| Microsomal Cytochrome P450 Dependent Oxidation of N-Hydroxyguanidines, Amidoximes, and Ketoximes: Mechanism of the Oxidative Cleavage of Their CN(OH) Bond with Formation of Nitrogen Oxides | 1998 | 89 | Pharmacogenetics and Drug Metabolism |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of hydroxyguanidine?
Which organizations hold the most patents related to hydroxyguanidine?
What are the main patent classification areas for hydroxyguanidine compounds?
What therapeutic applications have been patented for hydroxyguanidine?
Which researchers have published most frequently on hydroxyguanidine?